Original articleWhole-exome sequencing identifies novel homozygous mutation in NPAS2 in family with nonobstructive azoospermia
Key Words
Cited by (0)
R.R. has nothing to disclose. M.E.B. has nothing to disclose. C.C. has nothing to disclose. E.K. has nothing to disclose. J.S. has nothing to disclose. S.N.J. has nothing to disclose. Z.C.A. has nothing to disclose. M.B. has nothing to disclose. Y.Y. has nothing to disclose. C.H. has nothing to disclose. R.A.G. is interim chief scientific officer of Baylor Medical Genetics Laboratory. J.R.L. has stock ownership in 23 and Me and Ion Torrent Systems, is a paid consultant for Regeneron, is on the board of directors for Lasergen, and is a coinventor on multiple U.S. and European patents related to molecular diagnostics. D.J.L. has nothing to disclose. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from the chromosomal microarray analysis (CMA) and clinical exome sequencing offered in the Medical Genetics Laboratory (MGL; http://www.bcm.edu/geneticlabs/).
Supported by a K12 scholarship (to R.R.), a Male Reproductive Health Research (MRHR) Career Development Physician-Scientist Award (Grant HD073917–01) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Program (to D.J.L.), and in part by the National Institutes of Health National Human Genome Research Institute (Grants 5 U54 HG003273) (to R.A.G.) and (Grants RO1NS058529 and U54HG006542) (J.R.L.).